Another Case Made for Amarin's (AMRN) Vascepa Missing NCE Status
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/23/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
- One killed, three injured when man attacks Swedish school with sword
Amid New Patent, Amarin's (AMRN) Vascepa Might Still See Competition
October 31, 2012 11:16 AM EDTAmarin Corp. (Nasdaq: AMRN) shares are lower on the session following at least one analyst firm taking a bearish stance on its patent protection for Vascepa.
According to Summer Street analyst Bart Classen, patent coverage on Amarin's Vascepa remains "very narrow". The implication is that a generic form of... More
